Списки джерел: "Subcutaneous heterogeneity"

1

Xie, Yao, Yongli Ji, Yunrui Lu, Yuankun Ma, Hui Ni, Jian Shen, Hong Ma, et al. "Distinct Characteristics Between Perivascular and Subcutaneous Adipose-Derived Stem Cells." Diabetes 71, no. 2 (November 9, 2021): 321–28. http://dx.doi.org/10.2337/db20-1129.

Повний текст джерела

Анотація:

Adipose-derived stem cells (ADSCs) can differentiate into vascular lineages and participate in vascular remodeling. Perivascular ADSCs (PV-ADSCs) draw attention because of their unique location. The heterogeneity of subcutaneous (SUB) and abdominal ADSCs were well addressed, but PV-ADSCs’ heterogeneity has not been investigated. In this study, we applied single-cell analysis to compare SUB-ADSCs and PV-ADSCs regarding their subpopulations, functions, and cell fates. We uncovered four subpopulations of PV-ADSCs (Dpp4+, Col4a2+/Icam1+, Clec11a+/Cpe+, and Sult1e1+ cells), among which the Clec11a+ subpopulation potentially participated in and regulated PV-ADSC differentiation toward a smooth muscle cell (SMC) phenotype. Distinct characteristics between PV-ADSCs and SUB-ADSCs were revealed.

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Luong, Quyen, Jun Huang, and Kevin Y. Lee. "Deciphering White Adipose Tissue Heterogeneity." Biology 8, no. 2 (April 11, 2019): 23. http://dx.doi.org/10.3390/biology8020023.

Повний текст джерела

Анотація:

Adipose tissue not only stores energy, but also controls metabolism through secretion of hormones, cytokines, proteins, and microRNAs that affect the function of cells and tissues throughout the body. Adipose tissue is organized into discrete depots throughout the body, and these depots are differentially associated with insulin resistance and increased risk of metabolic disease. In addition to energy-dissipating brown and beige adipocytes, recent lineage tracing studies have demonstrated that individual adipose depots are composed of white adipocytes that are derived from distinct precursor populations, giving rise to distinct subpopulations of energy-storing white adipocytes. In this review, we discuss this developmental and functional heterogeneity of white adipocytes both between and within adipose depots. In particular, we will highlight findings from our recent manuscript in which we find and characterize three major subtypes of white adipocytes. We will discuss these data relating to the differences between subcutaneous and visceral white adipose tissue and in relationship to previous work deciphering adipocyte heterogeneity within adipose tissue depots. Finally, we will discuss the possible implications of adipocyte heterogeneity may have for the understanding of lipodystrophies.

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Boulet, Nathalie, David Estève, Anne Bouloumié, and Jean Galitzky. "Cellular heterogeneity in superficial and deep subcutaneous adipose tissues in overweight patients." Journal of Physiology and Biochemistry 69, no. 3 (November 25, 2012): 575–83. http://dx.doi.org/10.1007/s13105-012-0225-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Da, Yong, Ge Shen, Ming Zhou, Tao Wang, Dapeng Dong, Lina Bu, Yun Shao, Qiyun Sun, and Ruoying Yu. "Rapid subcutaneous progression after immunotherapy in pretreated patients with metastatic carcinoma: two case reports." Journal of International Medical Research 50, no. 4 (April 2022): 030006052210942. http://dx.doi.org/10.1177/03000605221094274.

Повний текст джерела

Анотація:

There is heterogeneity in cancer patients’ responses to immune checkpoint inhibitors (ICIs), including hyperprogression, which is very rapid tumor progression following immunotherapy, and pseudoprogression, which is an initial increase followed by a decrease in tumor burden or in the number of tumor lesions. This heterogeneity complicates clinical decisions because either premature withdrawal of the treatment or prolonged ineffective treatment harms patients. We presented two patients treated with ICIs with heterogeneous responses. One patient had Merkel cell carcinoma in the right thigh, and the other had nasopharyngeal squamous carcinoma. The first patient was treated with sintilimab and the second with sintilimab combined with abraxane. In the first patient, subcutaneous lesions grew substantially after the first cycle of treatment with sintilimab. In the second patient, subcutaneous lesions grew gradually after the second cycle of treatment with sintilimab combined with abraxane. In both cases, biopsy examination confirmed that newly emerged lesions were metastases of the primary tumor. These two cases remind clinicians that when subcutaneous nodules appear after treatment with ICIs, pathological biopsy is needed to determine the nature—pseudoprogression or rapid progression—of the disease course.

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Da, Yong, Ge Shen, Ming Zhou, Tao Wang, Dapeng Dong, Lina Bu, Yun Shao, Qiyun Sun, and Ruoying Yu. "Rapid subcutaneous progression after immunotherapy in pretreated patients with metastatic carcinoma: two case reports." Journal of International Medical Research 50, no. 4 (April 2022): 030006052210942. http://dx.doi.org/10.1177/03000605221094274.

Повний текст джерела

Анотація:

There is heterogeneity in cancer patients’ responses to immune checkpoint inhibitors (ICIs), including hyperprogression, which is very rapid tumor progression following immunotherapy, and pseudoprogression, which is an initial increase followed by a decrease in tumor burden or in the number of tumor lesions. This heterogeneity complicates clinical decisions because either premature withdrawal of the treatment or prolonged ineffective treatment harms patients. We presented two patients treated with ICIs with heterogeneous responses. One patient had Merkel cell carcinoma in the right thigh, and the other had nasopharyngeal squamous carcinoma. The first patient was treated with sintilimab and the second with sintilimab combined with abraxane. In the first patient, subcutaneous lesions grew substantially after the first cycle of treatment with sintilimab. In the second patient, subcutaneous lesions grew gradually after the second cycle of treatment with sintilimab combined with abraxane. In both cases, biopsy examination confirmed that newly emerged lesions were metastases of the primary tumor. These two cases remind clinicians that when subcutaneous nodules appear after treatment with ICIs, pathological biopsy is needed to determine the nature—pseudoprogression or rapid progression—of the disease course.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Haac, Bryce E., Nathan N. O'Hara, C. Daniel Mullins, Deborah M. Stein, Theodore T. Manson, Herman Johal, Renan Castillo, Robert V. O'Toole, and Gerald P. Slobogean. "Patient preferences for venous thromboembolism prophylaxis after injury: a discrete choice experiment." BMJ Open 7, no. 8 (August 2017): e016676. http://dx.doi.org/10.1136/bmjopen-2017-016676.

Повний текст джерела

Анотація:

ObjectiveLimited evidence for the optimal venous thromboembolism (VTE) prophylaxis regimen in orthopaedic trauma leads to variability in regimens. We sought to delineate patient preferences towards cost, complication profile, and administration route (oral tablet vs. subcutaneous injection).DesignDiscrete choice experiment (DCE).SettingLevel 1 trauma center in Baltimore, USA.Participants232 adult trauma patients (mean age 47.9 years) with pelvic or acetabular fractures or operative extremity fractures.Primary and secondary outcome measuresRelative preferences and trade-off estimates for a 1% reduction in complications were estimated using multinomial logit modelling. Interaction terms were added to the model to assess heterogeneity in preferences.ResultsPatients preferred oral tablets over subcutaneous injections (marginal utility, 0.16; 95% CI: 0.11 - 0.21,P<0.0001). Preferences changed in favor of subcutaneous injections with an absolute risk reduction of 6.98% in bleeding, 4.53% in wound complications requiring reoperation, 1.27% in VTE, and 0.07% in death from pulmonary embolism (PE). Patient characteristics (sex, race, type of injury, time since injury) affected patient preferences (P<0.01).ConclusionsPatients preferred oral prophylaxis and were most concerned about risk of death from PE. Furthermore, the findings estimated the trade-offs acceptable to patients and heterogeneity in preferences for VTE prophylaxis.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Raajendiran, Arthe, Christoph Krisp, David P. De Souza, Geraldine Ooi, Paul R. Burton, Renea A. Taylor, Mark P. Molloy, and Matthew J. Watt. "Proteome analysis of human adipocytes identifies depot-specific heterogeneity at metabolic control points." American Journal of Physiology-Endocrinology and Metabolism 320, no. 6 (June 1, 2021): E1068—E1084. http://dx.doi.org/10.1152/ajpendo.00473.2020.

Повний текст джерела

Анотація:

Adipocyte metabolism varies depending on anatomical location and the adipocyte protein composition may orchestrate this heterogeneity. We used SWATH proteomics in patient-matched human upper- (visceral and subcutaneous) and lower-body (glutealfemoral) adipocytes and detected 4,220 proteins and distinguishable regional proteomes. Upper-body adipocyte proteins were associated with glycolysis, de novo lipogenesis, mitochondrial dysfunction, and oxidative stress, whereas lower-body adipocyte proteins were associated with enhanced PPARα activation, fatty acid, and BCAA oxidation, TCA cycle flux, and oxidative phosphorylation.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Patel, Pavankumar, and Nicola Abate. "Role of Subcutaneous Adipose Tissue in the Pathogenesis of Insulin Resistance." Journal of Obesity 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/489187.

Повний текст джерела

Анотація:

Burden of obesity has increased significantly in the United States over last few decades. Association of obesity with insulin resistance and related cardiometabolic problems is well established. Traditionally, adipose tissue in visceral fat depot has been considered a major culprit in development of insulin resistance. However, growing body of the literature has suggested that adipose tissue in subcutaneous fat depot, not only due to larger volume but also due to inherent functional characteristics, can have significant impact on development of insulin resistance. There are significant differences in functional characteristics of subcutaneous abdominal/truncal versus gluteofemoral depots. Decreased capacity for adipocyte differentiation and angiogenesis along with adipocyte hypertrophy can trigger vicious cycle of inflammation in subcutaneous adipose tissue and subsequent ectopic fat deposition. It is important to shift focus from fat content to functional heterogeneity in adipose tissue depots to better understand the relative role of subcutaneous adipose tissue in metabolic complications of obesity. Therapeutic lifestyle change continues to be the most important intervention in clinical practice at any level of increased adiposity. Future pharmaceutical interventions aimed at improving adipose tissue function in various subcutaneous depots have potential to help maintain adequate insulin sensitivity and reduce risk for development of insulin resistance complications.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Vargas, Gracie, Manisha Chandalia, Yongquan Jiang, Himara Davila, Massoud Motamedi, and Nicola Abate. "Heterogeneity in Subcutaneous Adipose Tissue Morphology and Metabolic Complications in Overweight and Obese Women." Metabolic Syndrome and Related Disorders 11, no. 4 (August 2013): 276–82. http://dx.doi.org/10.1089/met.2013.0024.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Hadoke, Patrick W. F., Carol-Ann McIntyre, Gillian A. Gray, and Christine H. Buckley. "Functional heterogeneity of large and small resistance arteries isolated from biopsies of subcutaneous fat." General Pharmacology: The Vascular System 35, no. 3 (September 2000): 119–27. http://dx.doi.org/10.1016/s0306-3623(01)00085-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Добірка наукової літератури з теми "Subcutaneous heterogeneity"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Зміст

Статті в журналах з теми "Subcutaneous heterogeneity"